Enliven Therapeutics (ELVN) Prepaid Assets (2019 - 2026)
Enliven Therapeutics (ELVN) reported Prepaid Assets of $10.7 million for Q1 2026, up 125.4% on a YoY basis from $4.8 million in Q1 2025, and down 12.41% sequentially from $12.3 million in Q4 2025.
Enliven Therapeutics (ELVN) Prepaid Assets (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Prepaid Assets data on file, last reported at $10.7 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets rose 125.4% year-over-year to $10.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.7 million (up 125.4% YoY), and the FY2025 full-year result was $12.3 million, up 164.56% from the prior year.
- Prepaid Assets retreated to $10.7 million in Q1 2026, from $12.3 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $12.3 million in Q4 2025 to a low of $2.2 million in Q4 2022.
- A 5-year average of $5.5 million and a median of $5.1 million in 2025 frame the typical range for Prepaid Assets.
- Peak annual rise in Prepaid Assets reached 164.56% in 2025, while the deepest fall reached 28.28% in 2025.
- Tracing ELVN's Prepaid Assets over 5 years: stood at $2.2 million in 2022, then jumped by 33.02% to $2.9 million in 2023, then surged by 57.1% to $4.6 million in 2024, then jumped by 164.56% to $12.3 million in 2025, then fell by 12.41% to $10.7 million in 2026.
- Business Quant data shows ELVN's Prepaid Assets at $10.7 million in Q1 2026, $12.3 million in Q4 2025, and $5.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.74 Mn |
| Dec 31, 2025 | 12.26 Mn |
| Sep 30, 2025 | 5.12 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Mar 31, 2025 | 4.76 Mn |
| Dec 31, 2024 | 4.63 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 5.68 Mn |
| Mar 31, 2024 | 6.64 Mn |
| Dec 31, 2023 | 2.95 Mn |
| Sep 30, 2023 | 5.13 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Mar 31, 2023 | 5.90 Mn |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 3.92 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Dec 31, 2021 | 2.42 Mn |
| Sep 30, 2021 | 3.16 Mn |
| Jun 30, 2021 | 4.59 Mn |